Unveiling the potential anti‐cancer activity of calycosin against multivarious cancers with molecular insights: A promising frontier in cancer research

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Calycosin may be a potential candidate regarding chemotherapeutic agent, because already some studies against multivarious cancer have been made with this natural compound.

Aim

This review elucidated a brief overview of previous studies on calycosin potential effects on various cancers and its potential mechanism of action.

Methodology

Data retrieved by systematic searches of Google Scholar, PubMed, Science Direct, Web of Science, and Scopus by using keywords including calycosin, cancer types, anti‐cancer mechanism, synergistic, and pharmacokinetic and commonly used tools are BioRender, ChemDraw Professional 16.0, and ADMETlab 2.0.

Results

Based on our review, calycosin is available in nature and effective against around 15 different types of cancer. Generally, the anti‐cancer mechanism of this compound is mediated through a variety of processes, including regulation of apoptotic pathways, cell cycle, angiogenesis and metastasis, oncogenes, enzymatic pathways, and signal transduction process. These study conducted in various study models, including in silico, in vitro, preclinical and clinical models. The molecular framework behind the anti‐cancer effect is targeting some oncogenic and therapeutic proteins and multiple signaling cascades. Therapies based on nano‐formulated calycosin may make excellent nanocarriers for the delivery of this compound to targeted tissue as well as particular organ. This natural compound becomes very effective when combined with other natural compounds and some standard drugs. Moreover, proper use of this compound can reverse resistance to existing anti‐cancer drugs through a variety of strategies. Calycosin showed better pharmacokinetic properties with less toxicity in human bodies.

Conclusion

Calycosin exhibits excellent potential as a therapeutic drug against several cancer types and should be consumed until standard chemotherapeutics are available in pharma markets.

Related collections

Most cited references 116

Record: found
Abstract: found
Article: not found

Is Open Access

Cancer statistics, 2022

Rebecca Siegel, Kimberly D Miller, Hannah Fuchs … (2022)

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.

0 comments Cited 5840 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

Prashanth Rawla, Tagore Sunkara, Vinaya Gaduputi (2019)

Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. However, its toll is higher in more developed countries. Reasons for vast differences in mortality rates of pancreatic cancer are not completely clear yet, but it may be due to lack of appropriate diagnosis, treatment and cataloging of cancer cases. Because patients seldom exhibit symptoms until an advanced stage of the disease, pancreatic cancer remains one of the most lethal malignant neoplasms that caused 432,242 new deaths in 2018 (GLOBOCAN 2018 estimates). Globally, 458,918 new cases of pancreatic cancer have been reported in 2018, and 355,317 new cases are estimated to occur until 2040. Despite advancements in the detection and management of pancreatic cancer, the 5-year survival rate still stands at 9% only. To date, the causes of pancreatic carcinoma are still insufficiently known, although certain risk factors have been identified, such as tobacco smoking, diabetes mellitus, obesity, dietary factors, alcohol abuse, age, ethnicity, family history and genetic factors, Helicobacter pylori infection, non-O blood group and chronic pancreatitis. In general population, screening of large groups is not considered useful to detect the disease at its early stage, although newer techniques and the screening of tightly targeted groups (especially of those with family history), are being evaluated. Primary prevention is considered of utmost importance. Up-to-date statistics on pancreatic cancer occurrence and outcome along with a better understanding of the etiology and identifying the causative risk factors are essential for the primary prevention of this disease.

0 comments Cited 831 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

Impact of natural products on developing new anti-cancer agents.

Gordon M. Cragg, Paul G. Grothaus, David J Newman (2009)

0 comments Cited 276 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Abdullah Al Mamun:

ORCID: https://orcid.org/0000-0003-3839-9603

amamun42@gmail.com

Journal

Journal ID (nlm-ta): Cancer Med

Journal ID (iso-abbrev): Cancer Med

Journal ID (doi): 10.1002/(ISSN)2045-7634

Journal ID (publisher-id): CAM4

Title: Cancer Medicine

Publisher: John Wiley and Sons Inc. (Hoboken )

ISSN (Electronic): 2045-7634

Publication date (Electronic): 17 January 2024

Publication date Collection: February 2024

Volume: 13

Issue: 3 ( doiID: 10.1002/cam4.v13.3 )

Electronic Location Identifier: e6924

Affiliations

[ ¹ ] Biochemistry and Molecular Biology Primeasia University Dhaka Bangladesh

[ ² ] Biochemistry and Molecular Biology Mawlana Bhashani Science and Technology University Tangail Bangladesh

[ ³ ] Biotechnology and Genetic Engineering Mawlana Bhashani Science and Technology University Tangail Bangladesh

[ ⁴ ] Department of Genetic Engineering and Biotechnology, Faculty of Biological Science and Technology Jashore University of Science and Technology (JUST) Jashore Bangladesh

Author notes

[*] [* ] Correspondence

Abdullah Al Mamun, Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Santosh, Tangail 1902, Bangladesh.

Email: amamun42@ 123456gmail.com

Author information

Md Sohel https://orcid.org/0000-0001-8344-1976

Abdullah Al Mamun https://orcid.org/0000-0003-3839-9603

Article

Publisher ID: CAM46924 Other ID: CAM4-2023-07-3671.R2

DOI: 10.1002/cam4.6924

PMC ID: 10905684

PubMed ID: 38230908

SO-VID: dc5ae208-d68f-4a0f-b4d0-9a68b4f79966

License:

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

History

Date revision received : 11 December 2023

Date received : 31 July 2023

Date accepted : 30 December 2023

Page count

Figures: 7, Tables: 5, Pages: 26, Words: 11080

Custom metadata

source-schema-version-number 2.0

cover-date February 2024

details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.8 mode:remove_FC converted:01.03.2024

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: anti‐cancer perspective,calycosin,molecular pharmacology,nanoformulation,pharmacokinetics,synergistic

Data availability:

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: anti‐cancer perspective, calycosin, molecular pharmacology, nanoformulation, pharmacokinetics, synergistic

Unveiling the potential anti‐cancer activity of calycosin against multivarious cancers with molecular insights: A promising frontier in cancer research

Read this article at

Abstract

Background

Aim

Methodology

Results

Conclusion

Related collections

Karger: Oncology

Most cited references 116

Cancer statistics, 2022

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

Impact of natural products on developing new anti-cancer agents.

Author and article information

Contributors

Journal

Affiliations

Author notes

Author information

Article

History

Page count

Categories

Custom metadata

Comments

Comment on this article

Similar content 203

Cited by 1

Most referenced authors 1,437